Haleon PLC (HLN)
10.67
+0.08
(+0.76%)
USD |
NYSE |
Sep 27, 16:00
10.78
+0.11
(+1.03%)
After-Hours: 20:00
Haleon Research and Development Expense (Annual): 386.98M for Dec. 31, 2023
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 386.98M |
| December 31, 2022 | 371.50M |
| December 31, 2021 | 353.57M |
| Date | Value |
|---|---|
| December 31, 2020 | 390.17M |
| December 31, 2019 | 372.84M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
353.57M
Minimum
2021
390.17M
Maximum
2020
375.01M
Average
372.84M
Median
2019
Research and Development Expense (Annual) Benchmarks
| Adaptimmune Therapeutics PLC | 126.51M |
| Biodexa Pharmaceuticals PLC | -- |
| Verona Pharma PLC | 17.22M |
| NuCana PLC | 31.19M |
| Autolus Therapeutics PLC | 130.48M |